Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression

Cancer

Volumn 92, Issue 4, 2001, Pages 713-719

  Molica, Stefano ^a,b,c   Vitelli, Gaetano ^a,b   Levato, Domenico ^a,b   Giannarelli, Diana ^a,b   Gandolfo, Giuseppe Maria ^a,b  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Azienda Ospedialiera Pugliese Ciaccio ^*  (Italy)

Author keywords

Disease progression; Early chronic lymphocytic leukemia (CLL); Progression free survival (PFS); Soluble CD44

Indexed keywords

BETA 2 MICROGLOBULIN; CD5 ANTIGEN; HERMES ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BLOOD LEVEL; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 0035880701     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010815)92:4<713::AID-CNCR1374>3.0.CO;2-O     Document Type: Article

References (32)

1. Chronic lymphocytic leukemia
2. Chronic lymphocytic leukemia: Staging and prognostic factors
3. Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals
4. Is it time for a reassessment of prognostic features in B-cell chronic lymphocytic leukemia?
5. Bone marrow histologic pattern the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases
6. Lymphocyte doubling time in chronic lymphocytic leukaemia. Analysis of its prognostic significance
7. The serum β2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia
8. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia
9. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia
10. Adhesion molecules in B-chronic lymphoproliferative disorders
11. Serum levels of soluble intracellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers
12. Expression on leukemic cells and serum circulating levels of intracellular adhesion molecule-1 (ICAM-1) in B-cell chronic lymphocytic leukemia
13. Elevated serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) closely reflect tumor burden in chronic B-lymphocytic leukaemia
14. Cell adhesion receptors in lymphoma dissemination
15. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor
16. CD44 and its interaction with extracellular matrix
17. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer
18. CD44 expression predicts disease outcome in localized large B-cell lymphoma
19. Adhesion molecule expression on B-cell chronic lymphocytic leukemia cells: Malignant cell phenotypes define distinct disease subset
20. Increased serum levels of CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia
21. National-Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
22. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate analysis
23. Progression and survival studies in early chronic lymphocytic leukemia
24. Nonparametric estimation from incomplete observations
25. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Analyses and examples
26. Regression models and life tables
27. Natural history of chronic lymphocytic leukemia: On the progression and prognosis of early clinical stages
28. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): Results of randomized clinical trials on 162 patients
29. Natural history of stage A chronic lymphocytic leukaemia untreated patients
30. An aggressive subtype of B-CLL is characterized by strong CD44 expression and lack of CD11c
31. Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells
32. Chlorambucil in indolent chronic lymphocytic leukemia